JP5913353B2 - 腫瘍細胞毒性剤およびその方法 - Google Patents

腫瘍細胞毒性剤およびその方法 Download PDF

Info

Publication number
JP5913353B2
JP5913353B2 JP2013540910A JP2013540910A JP5913353B2 JP 5913353 B2 JP5913353 B2 JP 5913353B2 JP 2013540910 A JP2013540910 A JP 2013540910A JP 2013540910 A JP2013540910 A JP 2013540910A JP 5913353 B2 JP5913353 B2 JP 5913353B2
Authority
JP
Japan
Prior art keywords
cells
pharmaceutical composition
cancer
lactic acid
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013540910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500263A (ja
JP2014500263A5 (https=
Inventor
リン フォー，ホイ
リン フォー，ホイ
チュエン ロー，テック
チュエン ロー，テック
オン チュア，リー
オン チュア，リー
バヌ アリシン，ナルジャハン
バヌ アリシン，ナルジャハン
アブドュル．ラヒム，ラハ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiti Putra Malaysia (UPM)
Original Assignee
Universiti Putra Malaysia (UPM)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiti Putra Malaysia (UPM) filed Critical Universiti Putra Malaysia (UPM)
Publication of JP2014500263A publication Critical patent/JP2014500263A/ja
Publication of JP2014500263A5 publication Critical patent/JP2014500263A5/ja
Application granted granted Critical
Publication of JP5913353B2 publication Critical patent/JP5913353B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013540910A 2010-11-29 2010-11-29 腫瘍細胞毒性剤およびその方法 Expired - Fee Related JP5913353B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MY2010/000307 WO2012074351A1 (en) 2010-11-29 2010-11-29 Tumour cytotoxic agent and methods thereof

Publications (3)

Publication Number Publication Date
JP2014500263A JP2014500263A (ja) 2014-01-09
JP2014500263A5 JP2014500263A5 (https=) 2014-02-20
JP5913353B2 true JP5913353B2 (ja) 2016-04-27

Family

ID=46172112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540910A Expired - Fee Related JP5913353B2 (ja) 2010-11-29 2010-11-29 腫瘍細胞毒性剤およびその方法

Country Status (7)

Country Link
US (2) US9480721B2 (https=)
EP (1) EP2646042A4 (https=)
JP (1) JP5913353B2 (https=)
KR (1) KR101747815B1 (https=)
BR (1) BR112012021624A2 (https=)
SG (1) SG183544A1 (https=)
WO (1) WO2012074351A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405321A (zh) 2015-01-23 2017-11-28 坦普尔大学 短链脂肪酸在癌症预防中的应用
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
CN115135751B (zh) 2019-12-31 2025-02-18 Gi生物群系公司 发酵乳杆菌菌株及含有其的用于预防或治疗代谢疾病的组合物
WO2021172900A1 (ko) 2020-02-26 2021-09-02 주식회사 지아이바이옴 락토바실러스 헬베티쿠스 균주 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물
EP4223300A4 (en) * 2020-09-30 2024-09-25 Chengdu Kuachangaopu Medical Technology Co., Ltd. USE OF A PROBIOTIC CONSTITUENT AND PHARMACEUTICAL COMPOSITION CONTAINING A PROBIOTIC CONSTITUENT
JP7594826B2 (ja) * 2021-03-22 2024-12-05 ジーアイ バイオーム ラクトバチルス・プランタルムｇｂ１０４株及びそれを含むがんの予防又は処置のための組成物
TW202342077A (zh) * 2022-02-10 2023-11-01 南韓商Ｇｉ生物群系公司 使用包括植物乳桿菌菌株和抗癌劑的組合施用療法的用於預防或治療癌症的組合物
CN116144530B (zh) * 2022-11-17 2023-07-21 朗恒科技集团有限公司 一株植物乳杆菌ay01及其应用
KR20240123764A (ko) * 2023-02-06 2024-08-14 주식회사 지아이바이옴 락토바실러스 플란타룸 균주 및 면역세포의 병용 요법을 이용한 암 예방 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093447A1 (ja) * 2008-01-22 2009-07-30 National University Corporation Asahikawa Medical College 消化器癌に対する抗腫瘍剤
WO2010064373A1 (ja) * 2008-12-04 2010-06-10 国立大学法人広島大学 Ｉｌ－８阻害剤およびその製造方法
EP2417245A1 (en) 2009-04-09 2012-02-15 Universiti Putra Malaysia (UPM) Monogastric animal feed
MY158907A (en) * 2009-08-10 2016-11-30 Univ Putra Malaysia Upm Metabolites in animal feed

Also Published As

Publication number Publication date
US20130323215A1 (en) 2013-12-05
JP2014500263A (ja) 2014-01-09
AU2010365001A1 (en) 2012-08-30
KR101747815B1 (ko) 2017-06-15
BR112012021624A2 (pt) 2017-02-07
SG183544A1 (en) 2012-10-30
EP2646042A4 (en) 2014-07-23
WO2012074351A1 (en) 2012-06-07
EP2646042A1 (en) 2013-10-09
US9480721B2 (en) 2016-11-01
KR20130132398A (ko) 2013-12-04
US20160030492A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
JP5913353B2 (ja) 腫瘍細胞毒性剤およびその方法
US12186350B2 (en) Antitumor effect potentiator
US11229672B2 (en) Probiotics composition containing hericium erinaceus
KR102759260B1 (ko) 락토바실러스 플란타럼 hom3201 균주 및 이의 생균 제제, 제조 방법 및 용도
CN108624523B (zh) 胚芽乳酸杆菌tci378及其于减脂及改善肠胃功能的应用
CN102399718B (zh) 副干酪乳酸杆菌株gmnl‑133、用于改善异位性皮肤炎或其它过敏疾病的组合物及其用途
KR101680014B1 (ko) 김치로부터 분리한 염증성 장 질환 치료 효과를 갖는 유산균
JP2021524751A (ja) 組成物及びその使用
Vitheejongjaroen et al. Antioxidant activity of Bifidobacterium animalis MSMC83 and its application in set-style probiotic yoghurt
CN108570428B (zh) 乳酸乳球菌乳酸亚种ccfm1018、其发酵食品及其在制备药物中的应用
KR20260030121A (ko) 복합균 분말 제제 및 이의 제조 방법과 용도
CN102917715B (zh) 疾病的预防改善剂、持久力提高剂、抗疲劳剂、以及使用它们的药品和饮食品
Abd El-Gawad et al. Inhibitory effect of yoghurt and soya yoghurt containing bifidobacteria on the proliferation of Ehrlich ascites tumour cells in vitro and in vivo in a mouse tumour model
TWI398259B (zh) 副乾酪乳酸桿菌株ｇｍｎｌ－１３３用於改善異位性皮膚炎或其他過敏疾病之組合物及其用途
CN119662448A (zh) 一株发酵粘液乳杆菌及其在破壁灵芝孢子粉发酵中的应用
KR20180040894A (ko) 신규한 락토바실러스 플란타룸 Lb41 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물
CN118703365A (zh) 一株约氏乳杆菌及其在破壁灵芝孢子粉发酵中的应用
KR20180040899A (ko) 신규한 락토바실러스 플란타룸 Ln4 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물
CN117327616A (zh) Lactiplantibacillus plantarum ZN1及其应用
KR101712981B1 (ko) 산양유가 함유된 면역증진용 프로바이오틱스 분말의 제조방법
JP2014024776A (ja) Ｎａｓｈ予防治療剤
AU2010365001B2 (en) Tumour cytotoxic agent and methods thereof
JP7267536B2 (ja) 乳酸醗酵ニンジンの製造方法
JP4612971B2 (ja) ケフィア粒から分離したラクトコッカス属乳酸菌とそれを用いた食品の製造法
Taheri et al. Lactobacillus acidophilus Cytotoxicity Effect and Apoptosis in Human Bladder Carcinoma Cells: An In Vitro Study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160119

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160401

R150 Certificate of patent or registration of utility model

Ref document number: 5913353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees